Home › SEC Filings › Press Releases
Press Releases
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| AXSM | PRESS-RELEASE | bullish | 6/10 | Axsome Therapeutics announced FDA acceptance of its NDA for AXS-12 (reboxetine) to treat cataplexy in narcolepsy, with a | Jul 15, 2026 |
| QTTB | PRESS-RELEASE | bearish | 7/10 | Q32 Bio priced a $200 million underwritten public offering of common stock and pre-funded warrants, representing massive | Jul 14, 2026 |
| CBIO | PRESS-RELEASE | bearish | 7/10 | Crescent Biopharma priced an underwritten public offering of 8,094,793 ordinary shares at $14.50 per share plus pre-fund | Jul 14, 2026 |
| BIIB | PRESS-RELEASE | bullish | 7/10 | Biogen announced Phase 2 CELIA data for diranersen, an anti-tau ASO, showing clinical slowing on CDR-SB (26% at 60 mg) a | Jul 14, 2026 |
| QUCY | PRESS-RELEASE | neutral | 2/10 | Quantum Cyber announced a provisional patent filing for a modular drone launch system, but provided no financial details | Jul 14, 2026 |
| SILO | PRESS-RELEASE | bullish | 4/10 | Silo Pharma announced via press release that its wholly owned AI-agent subsidiary, QwikAgents, has been accepted into th | Jul 14, 2026 |
| ERNA | PRESS-RELEASE | neutral | 3/10 | Ernexa Therapeutics released a CEO Corner video discussing ERNA-101, its lead cell therapy candidate for ovarian cancer, | Jul 14, 2026 |
| KURA | PRESS-RELEASE | neutral | 5/10 | Kura Oncology announced an oral presentation of updated Phase 1a data from its FIT-001 trial of darlifarnib plus cabozan | Jul 14, 2026 |
| AVIR | PRESS-RELEASE | bullish | 5/10 | Atea Pharmaceuticals initiated a first-in-human Phase 1 trial of AT-587 for hepatitis E virus (HEV), a disease with no a | Jul 14, 2026 |
| SPRO | PRESS-RELEASE | bullish | 7/10 | Spero Therapeutics in-licensed global rights (ex-China) to SP001 (IBI355), a third-generation anti-CD40L antibody, from | Jul 14, 2026 |
| PMN | PRESS-RELEASE | bullish | 6/10 | ProMIS Neurosciences announced at AAIC 2026 that its lead Alzheimer's candidate, PMN310, demonstrated a dose-dependent r | Jul 14, 2026 |
| ERAS | PRESS-RELEASE | bearish | 7/10 | Erasca has priced an upsized public offering of 31,428,572 shares at $17.50/share, expecting ~$550M in gross proceeds. T | Jul 13, 2026 |
| MESO | PRESS-RELEASE | neutral | 5/10 | Mesoblast announced completion of enrollment (at least 300 patients) in its pivotal Phase 3 trial of rexlemestrocel-L fo | Jul 13, 2026 |
| BIIB | PRESS-RELEASE | bullish | 6/10 | FDA approved Biogen's sBLA for LEQEMBI IQLIK, a once-weekly subcutaneous injection initiation dose for early Alzheimer's | Jul 13, 2026 |
| ERAS | PRESS-RELEASE | bullish | 7/10 | Erasca reported encouraging preliminary Phase 1 data for ERAS-0015, its pan-RAS molecular glue, showing a 57% unconfirme | Jul 13, 2026 |
| EVO | PRESS-RELEASE | bearish | 8/10 | Evotec SE reported preliminary Q2 2026 results with EPS of -€0.69, a massive miss vs the €0.09 consensus (-911.8% surpri | Jul 13, 2026 |
| CPIX | PRESS-RELEASE | bullish | 7/10 | Cumberland Pharmaceuticals declared a special dividend of $1.50 per share and authorized a $5M buyback, returning capita | Jul 13, 2026 |
| ARTL | PRESS-RELEASE | neutral | 4/10 | Artelo Biosciences announced nonclinical results showing ART27.13 reduced neuropathic pain behaviors in a paclitaxel-ind | Jul 13, 2026 |
| ANIP | PRESS-RELEASE | bullish | 6/10 | ANI Pharmaceuticals reported positive topline Phase 4 data for ILUVIEN in chronic non-infectious uveitis affecting the p | Jul 13, 2026 |
| ALMR | PRESS-RELEASE | neutral | 4/10 | Alamar Biosciences announced a partnership with leading research universities to profile ~21,000 plasma samples from 10, | Jul 13, 2026 |
| EVAX | PRESS-RELEASE | neutral | 3/10 | Evaxion presented new preclinical data at the International Herpesvirus Workshop 2026 for its CMV vaccine program EVX-V1 | Jul 12, 2026 |
| VRXA | PRESS-RELEASE | neutral | 3/10 | VERAXA Biotech appointed Carl von Halem as Interim CFO, succeeding Torsten Bürgermeister. The company is in late-stage d | Jul 10, 2026 |
| ALMR | PRESS-RELEASE | bullish | 5/10 | Alamar Biosciences announced that its NULISA platform will be featured in over 140 poster and session presentations at t | Jul 10, 2026 |
| CUE | PRESS-RELEASE | bullish | 6/10 | Cue Biopharma announced a $50M private placement priced at $33.21/share, led by Cormorant Asset Management with particip | Jul 9, 2026 |
| MESO | PRESS-RELEASE | mixed | 6/10 | Mesoblast reported Q1 FY2026 EPS of -$0.07, missing consensus of -$0.03 by 133%. However, the company announced full-yea | Jul 9, 2026 |
| NBIX | PRESS-RELEASE | neutral | 1/10 | Neurocrine Biosciences, Inc. announced it will host a conference call on July 30, 2026 to discuss its Q2 2026 results. | Jul 9, 2026 |
| NRIX | PRESS-RELEASE | bullish | 8/10 | Nurix reported Q1 FY2026 revenue of $9.0M (consensus $15.3M, -41% miss) and EPS of -$0.81 vs consensus -$0.72 (-12.5% mi | Jul 9, 2026 |
| VRAX | PRESS-RELEASE | bearish | 7/10 | Virax Biolabs is raising $3.3M through exercise of preferred investment options at a reduced price of $6/share, while is | Jul 9, 2026 |
| INMB | PRESS-RELEASE | bullish | 5/10 | INmune Bio announced new Phase 2 imaging data for XPro1595 in early Alzheimer's disease, showing statistically significa | Jul 9, 2026 |
| CSTL | PRESS-RELEASE | neutral | 1/10 | Castle Biosciences, Inc. announced it will report its Q2 2026 results on July 30, 2026. | Jul 9, 2026 |